Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of ($0.25), $0.03 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $28.2 million versus the consensus estimate of $27.04 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2022 revenue of $115-135 million, versus the consensus of $134.6 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.